Merck’s London Research Hub To Begin Construction In April 2023

UK News

Merck’s London research hub to begin construction in April 2023

Merck has been planning a $1.3bn, 220,000 square foot research hub in London for six years but will finally begin construction in April this year, according to Mace, the newly appointed principal contractor.

The new hub is set to be located within Belgrove House on Euston Road, near King’s Cross railway station. This sets Merck within what is known as London’s Knowledge Quarter.

The new research facility is expected to house 800 researchers and office staff, including people working in marketing,financeandadministration. The majority of these staff will be acquired from the company’s existing sites around the country, however the development will open up 120 new jobs for scientists and technicians.

It is expected that researchers at the new facility will undertake early-stage research into age-related diseases, making it the only one of Merck’s labs to conduct this work outside of the US.

The facility will also be home to an education and outreach centre, a publicly accessible auditorium, a step-free entrance from King’s Cross as well as an educational outreach programme collaboration between Merck and Camden STEAM.

Merck’s press release states that “it has been designed using sustainable materials and includes an innovative double-skin façade to reduce solar gain. Carbon emissions generated through construction, operation and future fit-out will be reduced.”

NICE Recommends More Digital Mental Health Therapies For NHS Use

NICE has recommended eight new digital therapies to be used by the NHS for the treatment of mental health disorders

Eli Lilly And AbbVie Leave UK VPAS; Blow To UK Pharma Industry

Eli Lilly and AbbVie both announce that they will leave VPAS, causing concern that NHS patients may not receive breakthrough drug treatments

Cambridge’s Experimental Cancer Medicine Centre To Receive Funding

The ECMC in Cambridge is one of a handful of organisations to receive a share of £47.5 funding over the next five years

NHS To Offer Artificial Pancreas To Type 1 Diabetes Patients

The NHS will soon begin offering artificial pancreas to type 1 diabetes patients to help them manage their condition more effectively

Scottish Biotech Aims To Cure Common Cold

ScotBio has announced "promising initial results" from its attempt to extract a cure for the common cold from algae

NICE Recommends More Digital Mental Health Therapies For NHS Use

Eli Lilly And AbbVie Leave UK VPAS; Blow To UK Pharma Industry

Cambridge’s Experimental Cancer Medicine Centre To Receive Funding

NHS To Offer Artificial Pancreas To Type 1 Diabetes Patients

Scottish Biotech Aims To Cure Common Cold

Pharmafocus

Categories

Social Footprints